United Therapeutics says FDA reviews ralinepag NDA for pulmonary arterial hypertension

Reuters2026/07/29 10:35

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

United Therapeutics filed a New Drug Application with the FDA in June 2026 for ralinepag in pulmonary arterial hypertension.
Phase 3 ADVANCE OUTCOMES met its primary endpoint, cutting clinical worsening risk 55% versus placebo (HR 0.45; p<0.0001).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

United Therapeutics says FDA reviews ralinepag NDA for pulmonary arterial hypertension

You may also like

Crypto prices